Niina Veitonmaki

Niina Veitonmaki

Company: Molecular Partners AG

Job title: Director - In Vivo Immune-Oncology & Head of in Vivo Core


Novel Therapeutic Design of Tumor-targeted CD40 Agonistic DARPin® Molecule Leads to Antitumor Activity with Limited Systemic Toxicity 2:10 pm

Showcase Molecular Partners’ novel and modular immuno-oncology toolbox, designed as a targeted approach to activate CD40 selectively in the tumor microenvironment Presenting preclinical data demonstrating the multi-specific FAP x CD40 DARPin® molecule induced FAP-dependent activation of B cells, dendritic cells and macrophages Learn how FAP cross-linking is essential for anti-CD40 on antigen-presenting cells for activity…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.